Cardiovascular Toxicities of Androgen Deprivation Therapy

被引：39

作者：

Challa, Azariyas A. ^{[1
]}

Calaway, Adam Christopher ^{[2
]}

Cullen, Jennifer ^{[3
]}

Garcia, Jorge ^{[4
]}

Desai, Nihar ^{[5
,6
]}

Weintraub, Neal L. ^{[7
,8
]}

Deswal, Anita ^{[9
]}

Kutty, Shelby ^{[10
,11
]}

Vallakati, Ajay ^{[1
]}

Addison, Daniel ^{[1
]}

Baliga, Ragavendra ^{[1
]}

Campbell, Courtney M. ^{[1
]}

Guha, Avirup ^{[1
,12
]}

机构：

[1] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Cardiooncol Program,Div Cardiovasc Med, Columbus, OH 43210 USA

[2] Case Western Reserve Univ, Sch Med, Dept Urol, Univ Hosp Cleveland Med Ctr, Cleveland, OH USA

[3] Case Comprehens Canc Ctr, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA

[4] Case Western Reserve Univ, Sch Med, Univ Hosp Seidman Canc Ctr, Div Solid Tumor Oncol, Cleveland, OH USA

[5] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA

[6] Ctr Outcomes Res & Evaluat, New Haven, CT USA

[7] Augusta Univ, Vasc Biol Ctr, August, GA USA

[8] Augusta Univ, Med Coll Georgia, Dept Med, August, GA USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA

[10] Johns Hopkins Univ Hosp, Helen B Taussig Heart Ctr, Baltimore, MD 21287 USA

[11] Johns Hopkins Univ, Baltimore, MD USA

[12] UH Cleveland Med Ctr, Harrington Heart & Vasc Inst, Cleveland, OH 44106 USA

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2021年 / 22卷 / 06期

关键词：

Prostate cancer; Cardiovascular disease; Mortality; Side effects; Cardiotoxicity; Hormones; Prevention; METASTATIC PROSTATE-CANCER; OPEN-LABEL; SUPPRESSION THERAPY; HORMONE ANTAGONIST; RISK-FACTOR; MEN; TESTOSTERONE; DISEASE; RECEPTOR; METAANALYSIS;

D O I：

10.1007/s11864-021-00846-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Opinion statement Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treatment, has been associated with adverse cardiovascular events. Emerging data supports decreased cardiovascular risk of gonadotropin releasing hormone (GnRH) antagonists compared to agonists. Ongoing clinical trials are assessing the relative safety of different modalities of androgen deprivation therapy. Racial disparities in cardiovascular outcomes in prostate cancer patients are starting to be explored. An intriguing inquiry connects androgen deprivation therapy with reduced risk of COVID-19 infection susceptibility and severity. Recognition of the cardiotoxicity of androgen deprivation therapy and aggressive risk factor modification are crucial for optimal patient care.

引用

页数：20

共 104 条

[101] Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies [J].